Results 171 to 180 of about 35,569 (305)

Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.

Use of glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, initially developed as glucose-lowering therapies for the management of type 2 diabetes, continues to expand in parallel with our ...
Neumiller, Joshua J, Alicic, Radica
core   +1 more source

The Trojan horse of off-label glucagon-like peptide-1 receptor agonist use: Protecting patients through responsible practice. [PDF]

J Int Med Res
Belančić A, Jelaković B.
europepmc   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Pneumatosis intestinalis in a patient treated with a glucagon-like peptide-1 receptor agonist and prednisone. [PDF]

JCEM Case Rep
Sutton S, Ferguson Q, Gimpelevich R, Hemadeh O.   +3 more
europepmc   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Obesity in Classic Congenital Adrenal Hyperplasia: Mechanisms, Complications and Management

Clinical Endocrinology, EarlyView.
ABSTRACT Classic congenital adrenal hyperplasia (CCAH) is an autosomal recessive genetic disorder primarily caused by 21‐hydroxylase deficiency. Although the survival rate of patients has significantly improved with glucocorticoid replacement therapy, long‐term use of supraphysiological doses and multiple factors inherent to the disease itself have led
Jialin Mu, Yue Li, Meng Sun, Yulin Li, Panpan Li, Hui Zou   +5 more
wiley   +1 more source

Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist

Small molecule glucagon-like peptide-1 receptor agonist AZD0186 was developed to provide accessible and convenient treatment for a broad patient population with type 2 diabetes mellitus and/or obesity.
Boianelli, Alessandro, Boca, Simina M, Field, Joss, Omar, Sami, Polla, Magnus, Pettersen, Daniel, van Zuydam, Natalie, Snijder, Arjan, Melin, Johanna, Wallenius, Kristina, Brighton, Cheryl A, Grundevik, Pernilla, Janzén, David, Eckernäs, Daniel, Logue, Jennifer, Davies, Graeme, Qi, Weier, Hansen, Lars, Träff, Annika Maria, Fredberg, Monica, Lundqvist, Sara   +20 more
core  

Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Gastroenterology Res
Weng J, Huang A, Berake TB, Chen SL, Yan BM, Karagozian R.   +5 more
europepmc   +1 more source

Unveiling Gut Homeostasis Disruption in Sepsis: Towards an Integrated Mechanistic and Translational Roadmap

Cell Proliferation, EarlyView.
Elucidating the contribution of gut‐organ axes will provide new insights for developing combined therapeutic strategies against sepsis‐associated multiple organ dysfunction. ABSTRACT Sepsis, a life‐threatening clinical syndrome precipitated by a maladaptive host response to infection, is associated with substantial morbidity and high mortality rates ...
Yichen Bao, Lin Qi, Guijun Zou, Xingpeng Yang, Yizhao Ma, Zhifu Li, Xiaohui Du, Pengyue Zhao   +7 more
wiley   +1 more source

Depression following the initiation of glucagon-like-peptide-1 receptor agonist therapy: A multinational self-controlled case series study. [PDF]

J Intern Med
Yan VKC, Peng ZY, Wong VKC, Wong ICK, Chan EWY, Ou HT, Wan EYF.   +6 more
europepmc   +1 more source